There is data showing enhanced immune filtrations were associated with worse outcome of ER+ breast cancer86, opening up the possibility that BCK-associated immune alterations might contribute to the inferior outcome of patients with ESR1 mutant breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.